ABBV vs V: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Visa Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
AbbVie Inc. · Healthcare
$208.05
+4.5% upside to fair value
Grade C
High Quality
VS
Visa Inc. · Financial Services
$304.36
+37.7% upside to fair value
High Conviction
Grade A-
QuantHub Verdict
V has more upside to fair value
(+37.7%).
ABBV trades at a lower forward P/E
(14.9x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
V |
| Current Price |
$208.05 |
$304.36 |
| Fair Value Estimate |
$217.50 |
$419.00 |
| Upside to Fair Value |
+4.5%
|
+37.7%
|
| Market Cap |
$367.9B |
$586.8B |
| Forward P/E |
14.9x
|
23.7x
|
| EV / EBITDA |
16.7x
|
22.3x
|
| Price / Sales |
6.1x
|
14.2x
|
| Price / FCF |
20.9x
|
25.6x
|
| Revenue Growth YoY |
+8.6%
|
+11.3%
|
| Gross Margin |
83.7%
|
81.08%
|
| Operating Margin |
34.7%
|
59.18%
|
| Return on Equity |
-129.24%
|
54.22%
|
| Dividend Yield |
3.2% |
0.83% |
| FCF Yield |
4.78%
|
3.91%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billi…
Visa is the world's dominant payment network with $40B in net revenue (FY2025), 50%+ net margins, and a capital-light toll-booth model processing $14.2T in annual payment volume across 257.5B transactions. The business compounds at 10-12% revenue CAGR with operating leverage pushing EPS growth to 12-15% over a cycle, funded by $21.6B in annual free cash flow against only $1.5B in capex. At 28.0x …
Accumulation Zones
| Metric |
ABBV |
V |
| Zone Low |
$163.13 |
$265.00 |
| Zone High |
$184.88 |
$300.00 |
| In Buy Zone? |
No
|
No
|